60P Real-life use of Oncotype DX Breast Recurrence Score® test for the management of patients with node-negative and node-positive breast cancer in the autonomous community of Galicia (Spain)

I Fernandez-Perez,S Antolin Novoa,L De Paz Arias,L Vazquez Tuñas,M.E Perez Lopez,S Varela Ferreiro,A.Q Gonzalez Quintas,C Senin Estor,J.F Cueva Banuelos,C Hagen,L Inglada-Pérez,D Pereiro,L Calvo-Martinez,I Carou,L Iglesias Rey,A Saenz De Miera,T García-Caballero

doi:10.1016/j.annonc.2021.03.074

60P Real-life use of Oncotype DX Breast Recurrence Score® test for the management of patients with node-negative and node-positive breast cancer in the autonomous community of Galicia (Spain)

I Fernandez-Perez, S Antolin Novoa + Show 15 more

Open Access

https://doi.org/10.1016/j.annonc.2021.03.074

Copy DOI

Journal: Annals of Oncology	Publication Date: May 1, 2021
License type: publisher-specific-oa

Affiliation: Complexo Hospitalario Universitario A Coruña, University of Santiago de Compostela, Complejo Hospitalario de Pontevedra, Povisa Hospital, University Hospital Complex Of Vigo, Universidad Complutense de Madrid

#Oncotype DX Breast Recurrence Score #Early Stage Breast Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Oncotype DX® is a 21-gene assay to guide adjuvant treatment decisions in HR+, HER2- early stage breast cancer. The aim of the study was to evaluate the impact of Recurrence Score® (RS) on decision-making (% change in treatment recommendation), to assess real-life utilization of Oncotype DX test in node-negative, micrometastases, and 1-3 positive lymph nodes patients.

Full Text